Extension of the Distributed Delay Approach to Model Delayed Outcomes Involving Loss Mechanism During the Delay Process 2018 年 10 月 8 日 By webdev
Development of a PBPK Model for Docetaxel as a CYP3A Substrate and Accounting for Binding to Multiple Plasma Proteins 2018 年 10 月 8 日 By webdev
Interpretation of Dose-dependent Pharmacokinetics of Ruzasvir Using Both Physiologically-based Pharmacokinetic and Population Pharmacokinetic Modeling Approaches 2018 年 10 月 8 日 By webdev
Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy 2018 年 10 月 8 日 By webdev
Clinical Trial Simulation (CTS) for a New Rapidly Absorbed Paracetamol Formulation (NP) Development from the Conventional Paracetamol Tablet (CP) 2018 年 10 月 8 日 By webdev
Impact of Free Fatty Acids on Prediction of Unbound Fraction of Cefazolin and Diazepam in Plasma of Full-term Neonates 2018 年 10 月 8 日 By webdev
Application of Feto-maternal Physiologically-based Pharmacokinetic Model to Predict Emtricitabine Concentration During Pregnancy 2018 年 10 月 8 日 By webdev
Modeling Double Peak Phenomenon and In Vitro-In Vivo Correlation (IVIVC) in Pharmacokinetics (PK) for Clinical Trial Simulation (CTS) of Virtual Bioequivalence (BE) Studies 2018 年 10 月 8 日 By webdev
Development of a Population Pharmacokinetic Model for Binimetinib with Subsequent Exposure-response Analyses in NRAS Mutant Melanoma 2018 年 10 月 8 日 By webdev
A Product-profile-driven Clinical Utility Index (CUI) Analysis to Balance Benefits and Risks for Dose Selection in Oncology 2018 年 10 月 8 日 By webdev